Peter Greenleaf

Peter Greenleaf

Vorsitzender bei
Maryland Venture Fund

Vermögen: 29 Mio $ am 31.05.2026

56 Jahre
Health Technology
Finance
Commercial Services

Profil

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
02.03.2026 1.840.379 ( 1,43 % ) 28 Mio $ 31.05.2026
0,71 %
02.04.2026 24.681 ( 0,71 % ) 653 306 $ 31.05.2026

Aktuelle Nachrichten zu Peter Greenleaf

Aktive Positionen von Peter Greenleaf

UnternehmenPositionBeginn
Vorsitzender -
Vorsitzender 17.12.2020
Berater -

Ehemalige bekannte Positionen von Peter Greenleaf

UnternehmenPositionEnde
AURINIA PHARMACEUTICALS INC. Vorstandsvorsitzender 23.03.2026
ANTARES PHARMA, INC. Direktor/Vorstandsmitglied 24.05.2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Vorsitzender 22.03.2022
AVALO THERAPEUTICS, INC. Vorstandsvorsitzender 15.04.2019
KIORA PHARMACEUTICALS, INC. Direktor/Vorstandsmitglied 03.01.2020
Sehen Sie sich die Erfahrung von Peter Greenleaf im Detail an

Ausbildung von Peter Greenleaf

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

69

Beziehungen ersten Grades

33

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Börse
  2. Insiders
  3. Peter Greenleaf
-40 %: Exklusive Verlängerung
T
:
:
PROFITIEREN SIE JETZT